Table I.
Demographic and baseline characteristics (n = 34)
| No. | % | ||
|---|---|---|---|
| Age (years) | Median (range) | 60 (26-79) | |
| Time from diagnosis (months) | Median (range) | 30.0 (11.0-124.9) | |
| Histological type | Serous | 23 | 67.6 |
| adenocarcinoma | |||
| Othera | 9 | 26.5 | |
| Undetermined | 2 | 5.9 | |
| Tumor grade at diagnosis | 2 | 5 | 14.7 |
| 3 | 26 | 76.5 | |
| 4 | 1 | 2.9 | |
| UK | 2 | 5.9 | |
| Residual tumor | Optimally debulked <1b | 25 | 73.5 |
| Non-optimally debulkedc | 9 | 26.5 | |
| BRCA | Wild type | 10 | 29.4 |
| Mutated | 3d | 8.8 | |
| Unknown | 21 | 61.8 | |
| Number of previous lines of chemotherapy | Median (range) | 3 (2-10) | |
| 2 | 10 | 29.4 | |
| 3 | 10 | 29.4 | |
| ≥4 | 14 | 41.2 | |
| Platinum-free interval (months) | 6-12 | 22 | 64.7 |
| >12 | 12 | 35.3 | |
UK = unknown.
a
Adenocarcinoma not otherwise specified (NOS), clear cell, endometrioid (n = 4), mucinous, primitive peritoneal and yolk sac tumor.
b
Residual tumor <1 cm.
c
Residual tumor ≥1 cm (n = 7) or localized peritoneal seeding (n = 2).
d
BRCA1 (n = 1) and BRCA2 (n = 2).